Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ROIV
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Richard Pulik CFO | ROIV Roivant Sciences Ltd. | Sale | 47,635 | $41.89 | $2.0M Sale | Form 4 ↗ |
| Nov 11, 2026 | Richard Pulik CFO | ROIV Roivant Sciences Ltd. | Sale | 82,170 | $42.03 | $3.5M Sale | Form 4 ↗ |
| Nov 11, 2026 | Richard Pulik CFO | ROIV Roivant Sciences Ltd. | Sale | 45,195 | $41.47 | $1.9M Sale | Form 4 ↗ |
| Nov 10, 2026 | Richard Pulik CFO | ROIV Roivant Sciences Ltd. | Sale | 125,000 | $41.20 | $5.2M Sale | Form 4 ↗ |
| Nov 10, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 29,749 | $41.00 | $1.2M Sale | Form 4 ↗ |
| Nov 10, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 158,194 | $40.44 | $6.4M Sale | Form 4 ↗ |
| Nov 3, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $36.31 | $7.3M Sale | Form 4 ↗ |
| Oct 28, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $36.59 | $7.3M Sale | Form 4 ↗ |
| Oct 20, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 14,144 | $35.42 | $501.0K Sale | Form 4 ↗ |
| Oct 20, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 185,856 | $35.09 | $6.5M Sale | Form 4 ↗ |
| Sep 15, 2026 | Epperly Melissa B, Director | ROIV Roivant Sciences Ltd. | Sale | 600 | $40.38 | $24.2K Sale | Form 4 ↗ |
| Sep 15, 2026 | Epperly Melissa B, Director | ROIV Roivant Sciences Ltd. | Sale | 4,338 | $39.65 | $172.0K Sale | Form 4 ↗ |
| Sep 15, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | Sale | 400 | $40.45 | $16.2K Sale | Form 4 ↗ |
| Sep 15, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | Sale | 4,712 | $39.68 | $187.0K Sale | Form 4 ↗ |
| Sep 8, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | Sale | 20,000 | $39.90 | $798.0K Sale | Form 4 ↗ |
| Aug 28, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 33,818 | $36.44 | $1.2M Sale | Form 4 ↗ |
| Aug 28, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 166,182 | $35.63 | $5.9M Sale | Form 4 ↗ |
| Aug 21, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 144,756 | $36.48 | $5.3M Sale | Form 4 ↗ |
| Aug 20, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 17,519 | $37.30 | $653.5K Sale | Form 4 ↗ |
| Aug 19, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 172,899 | $37.17 | $6.4M Sale | Form 4 ↗ |
| Aug 18, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 31,801 | $37.18 | $1.2M Sale | Form 4 ↗ |
| Aug 18, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 105,141 | $36.59 | $3.8M Sale | Form 4 ↗ |
| Aug 17, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 284,707 | $36.25 | $10.3M Sale | Form 4 ↗ |
| Aug 14, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 243,177 | $36.23 | $8.8M Sale | Form 4 ↗ |
| Jul 27, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $34.95 | $7.0M Sale | Form 4 ↗ |
| Jun 30, 2026 | Meghan Fitzgerald Director | ROIV Roivant Sciences Ltd. | Sale | 10,000 | $34.90 | $349.0K Sale | Form 4 ↗ |
| Jun 30, 2026 | Keith S. Manchester Director | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $35.45 | $7.1M Sale | Form 4 ↗ |
| Jun 30, 2026 | Keith S. Manchester Director | ROIV Roivant Sciences Ltd. | Sale | 12,380 | $35.28 | $436.8K Sale | Form 4 ↗ |
| Jun 30, 2026 | Daniel Allen Gold Director | ROIV Roivant Sciences Ltd. | Sale | 12,380 | $35.28 | $436.8K Sale | Form 4 ↗ |
| Jun 30, 2026 | QVT Financial LP | ROIV Roivant Sciences Ltd. | Sale | 12,380 | $35.28 | $436.8K Sale | Form 4 ↗ |
| Jun 29, 2026 | Epperly Melissa B, Director | ROIV Roivant Sciences Ltd. | Sale | 2,748 | $34.71 | $95.4K Sale | Form 4 ↗ |
| Jun 29, 2026 | Epperly Melissa B, Director | ROIV Roivant Sciences Ltd. | Sale | 15,002 | $34.32 | $514.9K Sale | Form 4 ↗ |
| Jun 29, 2026 | Keith S. Manchester Director | ROIV Roivant Sciences Ltd. | Sale | 600,000 | $34.59 | $20.8M Sale | Form 4 ↗ |
| Jun 29, 2026 | Keith S. Manchester Director | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $34.44 | $6.9M Sale | Form 4 ↗ |
| Jun 29, 2026 | Daniel Allen Gold Director | ROIV Roivant Sciences Ltd. | Sale | 600,000 | $34.59 | $20.8M Sale | Form 4 ↗ |
| Jun 29, 2026 | Daniel Allen Gold Director | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $34.44 | $6.9M Sale | Form 4 ↗ |
| Jun 29, 2026 | QVT Financial LP | ROIV Roivant Sciences Ltd. | Sale | 600,000 | $34.59 | $20.8M Sale | Form 4 ↗ |
| Jun 29, 2026 | QVT Financial LP | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $34.44 | $6.9M Sale | Form 4 ↗ |
| Jun 26, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 500,000 | $34.08 | $17.0M Sale | Form 4 ↗ |
| Jun 26, 2026 | Keith S. Manchester Director | ROIV Roivant Sciences Ltd. | Sale | 325,000 | $34.07 | $11.1M Sale | Form 4 ↗ |
| Jun 26, 2026 | Keith S. Manchester Director | ROIV Roivant Sciences Ltd. | Sale | 300,783 | $33.92 | $10.2M Sale | Form 4 ↗ |
| Jun 26, 2026 | Daniel Allen Gold Director | ROIV Roivant Sciences Ltd. | Sale | 325,000 | $34.07 | $11.1M Sale | Form 4 ↗ |
| Jun 26, 2026 | Daniel Allen Gold Director | ROIV Roivant Sciences Ltd. | Sale | 300,783 | $33.92 | $10.2M Sale | Form 4 ↗ |
| Jun 26, 2026 | QVT Financial LP | ROIV Roivant Sciences Ltd. | Sale | 325,000 | $34.07 | $11.1M Sale | Form 4 ↗ |
| Jun 26, 2026 | QVT Financial LP | ROIV Roivant Sciences Ltd. | Sale | 300,783 | $33.92 | $10.2M Sale | Form 4 ↗ |
| Jun 25, 2026 | Mayukh Sukhatme President & CIO, Director | ROIV Roivant Sciences Ltd. | Sale | 500,000 | $34.13 | $17.1M Sale | Form 4 ↗ |
| Jun 24, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 46,234 | $33.51 | $1.5M Sale | Form 4 ↗ |
| Jun 24, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 153,766 | $33.05 | $5.1M Sale | Form 4 ↗ |
| May 22, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $30.27 | $6.1M Sale | Form 4 ↗ |
| Apr 20, 2026 | Eric Venker President & Immunovant CEO | ROIV Roivant Sciences Ltd. | Sale | 200,000 | $29.59 | $5.9M Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 4:58 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances